Coherus Biosciences Inc (NASDAQ: CHRS) Could Soon Experience A Sharp Increase In Its Share Price.

In the last trading session, 1.53 million shares of the Coherus Biosciences Inc (NASDAQ:CHRS) were traded, and its beta was 0.51. Most recently the company’s share price was $2.36, and it changed around -$0.04 or -1.67% from the last close, which brings the market valuation of the company to $262.81M. CHRS currently trades at a discount to its 52-week high of $8.65, offering almost -266.53% off that amount. The share price’s 52-week low was $1.43, which indicates that the current value has risen by an impressive 39.41% since then. We note from Coherus Biosciences Inc’s average daily trading volume that its 10-day average is 2.67 million shares, with the 3-month average coming to 4.32 million.

Coherus Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CHRS as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Coherus Biosciences Inc is expected to report earnings per share of -$0.23 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Coherus Biosciences Inc (NASDAQ:CHRS) trade information

Instantly CHRS has showed a red trend with a performance of -1.67% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -29.13% year-to-date, but still up 3.51% over the last five days. On the other hand, Coherus Biosciences Inc (NASDAQ:CHRS) is -2.07% down in the 30-day period. We can see from the shorts that 25.91 million shares have been sold at a short interest cover period of 9.28 day(s).

The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 73.78% from its current value. Analyst projections state that CHRS is forecast to be at a low of $7 and a high of $11.

Coherus Biosciences Inc (CHRS) estimates and forecasts

Coherus Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -36.90 percent over the past six months and at a 100.51% annual growth rate that is well above the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 69.30% in revenue this quarter, and will report an increase of 42.10% in the next quarter. The year-over-year growth rate is expected to be 1.80%, up from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $81.7 million in revenue for the current quarter. 5 analysts expect Coherus Biosciences Inc to make $53.68 million in revenue for the quarter ending Jun 2024. Analysts predict that the company’s current quarter sales will jump, forecast at 72.20%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.73%.

CHRS Dividends

Coherus Biosciences Inc’s next quarterly earnings report is expected to be released on March 13.

Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.35% of Coherus Biosciences Inc shares, and 78.04% of them are in the hands of institutional investors. The stock currently has a share float of 79.12%. Coherus Biosciences Inc stock is held by 221 institutions, with Blackrock Inc. being the largest institutional investor. By Jun 29, 2023, it held 16.71% of the shares, which is about 15.79 million shares worth $67.41 million.

Vanguard Group Inc, with 9.37% or 8.85 million shares worth $37.79 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 2.73 million shares worth $11.66 million, making up 2.89% of all outstanding shares. On the other hand, JP Morgan Small Cap Growth Fund held roughly 2.44 million shares worth around $10.41 million, which represents about 2.58% of the total shares outstanding.